XML 52 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangement - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Apr. 05, 2016
Jun. 30, 2016
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Carrying value   $ 27,623,000 $ 27,623,000   $ 27,613,000  
Paid-in-kind interest     2,604,000 $ 265,000    
Sanofi-Aventis Deutschland GmbH | Mortgage Loan            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Carrying value   17,600,000 $ 17,600,000      
License and Collaboration Agreement with Sanofi            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Profits and losses sharing percentage 35.00%   35.00%      
Maximum secured loan facility           $ 175,000,000
Senior notes, effective interest rate           8.50%
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Profits and losses sharing percentage 65.00%   65.00%      
Collaboration agreements expiration date     Apr. 04, 2016      
Deferred revenue from collaboration product shipments   150,000,000 $ 150,000,000      
Milestone receivable   50,000,000 50,000,000      
Deferred cost   22,700,000 22,700,000      
Company's total portion of profit sharing   300,000        
Maximum secured loan facility   175,000,000 175,000,000      
Carrying value   70,300,000 70,300,000      
Secured loan facility, amount borrowed     70,300,000      
Secured loan facility, amount earned   300,000        
Secured loan facility, amount owed   70,000,000 70,000,000      
Paid-in-kind interest     4,300,000      
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Company's total portion of loss sharing     70,000,000      
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue from collaboration product shipments   $ 17,700,000 $ 17,700,000